# AMT-116 in Patients with Solid Tumors

Source: https://onco.cc/trials/nct06782334/  
OnCo record `nct06782334` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AMT-116 in advanced solid tumours, run by Multitude Therapeutics Inc., now recruiting.

## Summary

AMT-116 in Patients with Solid Tumors is a phase 1/2 interventional study registered as NCT06782334 by Multitude Therapeutics Inc., with 144 participants planned, started 2024-05-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: AMT-116.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06782334
- Phase: 1/2
- Setting: Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors
- Sponsor: Multitude Therapeutics Inc.
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT06782334: https://clinicaltrials.gov/study/NCT06782334

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AMT-116](https://onco.cc/drugs/amt-116/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06782334.json